Biopharm Reports publishes new market findings on current practices, developments, trends, growth, shrinkage and opportunities in the cancer molecular diagnostics field.
Online PR News – 24-January-2014 – London – Advances in cancer molecular and cellular biology and the wider availability of more advanced laboratory techniques, are driving improved diagnostic and therapeutic strategies. Today, a wide range of diagnostic techniques are used, notably immunohistochemical, imaging, microscopy and antibody methodologies. However, this field is looking increasingly to Molecular Diagnostics methods to address long-standing limitations of established methods and these include the need for earlier detection of the disease, to allow the development of easier screening and diagnostic procedures and to provide insights at the disease level to enable better therapeutic choices to be made. The last decade has seen significant advances in molecular cancer diagnostic techniques such as PCR and Microarray and more recently, in the development of powerful Next-Generation Sequencing methods.
A new market study of cancer molecular diagnostics published this month by Biopharm Reports reveals the progress of developments in this field. This study, which involved the participation of 596 experienced physicians and research scientists, investigated the use molecular techniques and applications, molecular biomarkers, leading suppliers and other key areas. Findings show that while cancer diagnostics is dominated by non-molecular techniques such as immunohistochemistry and imaging, this study found that the most rapidly developing diagnostic areas are Next-Generation Sequencing (NGS), Mass Spectrometry (MS), Microarray and the study of Circulating Tumour Cells (CTCs) and Cancer Stem Cells (CSCs).
Biopharm Reports carries out market studies of techniques, methods, and instrumentation used in life science and clinical laboratories. These are conducted through specialist groups of experienced end-users and practitioners, and therefore findings are based on 'real world' market data.